Remote SWEATSkin PATCH for Monitoring Breast Cancer Therapeutic Responsebroad
SWEATPATCH · Horizon Europe grant · 2024-04-01–2028-03-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2023-PATHFINDEROPEN-01 · scheme HORIZON-EIC · topic HORIZON-EIC-2023-PATHFINDEROPEN-01-01. CORDIS record →
Objective
Breast Cancer (BC) is the most common cancer in Europe. In most cases, BC will present at a locally advanced or distant stage, which requiresanticancer drugs. However, there is no guarantee that the favorable drug benefit/risk balance will align with expectations at an individual level or be maintained over time. Therefore, monitoring tumor response to treatment is critical for timely adjusting the therapeutic strategy to improve patients’ outcomes. To fulfill this unmet medical need,SWEATPATCH proposesan innovative non- invasive approach to monitor in real-time BC response to treatment, based on emerging odorous biomarkers, namely volatile organic compounds (VOCs) from sweat emanated from the breast skin. Due to their connection to breast tumor metabolism, sweat VOCs are promising candidate biomarkers for monitoring tumor response to treatment.SWEATPATCH breakthrough relies on a radically-new technology with cutting-edge straintronic microwave based on phononic metamaterials and nanomaterials chemtronics technologies to solve scientific bottlenecks for sweat VOCs analysis in the near field of cancer cells.SWEATPATCH will gather an interdisciplinary consortium of leading experts in materials, sensors, data processing, and translational/clinical oncology, from 6 countries. The consortium will develop a groundbreaking wireless Lab-on-a-Patch to (1) monitor BC therapeutic response directly from the breast surface using a novel biocompatible flexible patch combined with specific data analysis that (2) will also be adaptable to in vitro 3D culture systems of patients’ derived organoids, a tumor model avatar created from patients’ BC, which will be used for drug screening to modelize tumor response to treatment.SWEATPATCH will convey a considerable conceptual leap that will shift the current healthcare paradigm from «one-size-fit-all» monitoring to «a smart real-time personalized monitoring»synchronized to tumor biology to reach precision oncology.
Beneficiaries (12)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| CENTRALE LILLE INSTITUT | FR | coordinator | €595,182 | |
| UNIVERSITE DE LILLE | FR | participant | €407,741 | |
| UNIVERSITE DE BORDEAUX | FR | participant | €388,931 | |
| UNIVERSITAT POLITECNICA DE VALENCIA | ES | participant | €356,250 | |
| CARETRONIC RAZVOJ IN PROIZVODNJA NAPREDNIH INFORMACIJSKIH RESITEV DOO | SI | participant | €291,250 | Yes |
| ISTITUTO ROMAGNOLO PER LO STUDIO DEI TUMORI DINO AMADORI - IRST SRL | IT | participant | €238,984 | |
| FONDAZIONE CASA SOLLIEVO DELLA SOFFERENZA | IT | participant | €201,345 | |
| ENDRESS AND HAUSER DIGITAL SOLUTIONS DEUTSCHLAND GMBH | DE | participant | €191,250 | |
| CENTRE OSCAR LAMBRET | FR | thirdParty | €0 | |
| INSTITUT POLYTECHNIQUE DE BORDEAUX | FR | thirdParty | €0 | |
| INVENSENSE ITALY S.R.L. | IT | participant | €0 | |
| NEUROLANE LTD | UK | associatedPartner | — | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.